Background: Despite international initiatives on collaboration within the field of rare
diseases, patient access to orphan medicinal products (OMPs) and healthcare services …

Objectives Rare diseases are recognized as non-prevalent health disorders. Availability,
accessibility, and affordability of Orphan Drugs (ODs), alongside genetic testing, are the …

Background Reimbursement policies influence access of patients to orphan drugs in the
European countries. Objectives To provide a comprehensive description of orphan drug …

Background The reimbursement of orphan drugs (OD) is an increasingly important for
country policymakers, and still insufficiently understood, especially in Central and Eastern …

Objective: To review the reimbursement recommendations issued by selected European
health technology assessment agencies for orphan drugs and the reimbursement status of …

Introduction Although there is a significant utilization gap of biologic medicines in the EU,
many studies estimate equity in patient access to biopharmaceuticals only based on their …

The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on
the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD). It is …

Background: Despite calls for the use of real-world data, the rare diseases (RD) treatment
landscape suffers from a scarcity of data referred to orphan medicinal products (OMP) use at …

Objective This article reviews the assessment pathways that have been implemented
worldwide to facilitate access to drugs for patients with rare diseases. Methods The …

Objectives: The aim of this study was to characterize the reimbursement policy for orphan
drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability …